Xuan Liu

TL;DR: The findings reveal that OA@BCMNs may provide a clinical basis for improving oncolytic virotherapy by overcoming undesired antiviral immunity and enhancing cancer cell selectivity via biomimetic synthesis approaches.

TL;DR: The E6F6-like mAbs may provide a novel immunotherapeutic agent against human chronic HBV infection and was possibly associated with its effective in vivo opsonophagocytosis for viral clearance.

TL;DR: The ASPIRE nanovaccine as discussed by the authors is derived from recombinant adenovirus-infected dendritic cells in which specific peptide-major histocompatibility complex class I (pMHC-I), anti-PD1 antibody and B7 co-stimulatory molecules are simultaneously anchored by a programmed process.

TL;DR: This new humanised mouse model recapitulates the liver cirrhosis induced by human HBV infection, thus providing research opportunities for understanding viral immune pathophysiology and testing antiviral therapies in vivo.

TL;DR: The receptor-mediated antiviral effect of hNTCP-MVs to trick HBV is demonstrated and novel opportunities for further development of antiviral strategies in nanomedicine are offered.